IKAROS and MENIN in synergy in AML.
Jones, LM; Starczynowski, DT.
2022;
3:528-529.
Blocking UBE2N abrogates oncogenic immune signaling in acute myeloid leukemia.
Barreyro, L; Sampson, AM; Ishikawa, C; Hueneman, KM; Choi, K; Pujato, MA; Chutipongtanate, S; Wyder, M; Haffey, WD; O'Brien, E; et al.
Science Translational Medicine.
2022;
14.
Momelotinib is a highly potent inhibitor of FLT3-mutant AML.
Azhar, M; Kincaid, Z; Kesarwani, M; Ahmed, A; Wunderlich, M; Latif, T; Starczynowski, D; Azam, M.
Blood Advances.
2022;
6:1186-1192.
TRAF6 functions as a tumor suppressor in myeloid malignancies by directly targeting MYC oncogenic activity.
Muto, T; Guillamot, M; Yeung, J; Fang, J; Bennett, J; Nadorp, B; Lasry, A; Redondo, LZ; Choi, K; Gong, Y; et al.
Cell Stem Cell.
2022;
29:298-314.e9.
The deubiquitinase USP15 modulates cellular redox and is a therapeutic target in acute myeloid leukemia.
Niederkorn, M; Ishikawa, C; M. Hueneman, K; Bartram, J; Stepanchick, E; R. Bennett, J; E. Culver-Cochran, A; Bolanos, LC; Uible, E; Choi, K; et al.
Leukemia.
2022;
36:438-451.
Mitochondrial Fragmentation Triggers Ineffective Hematopoiesis in Myelodysplastic Syndromes.
Aoyagi, Y; Hayashi, Y; Harada, Y; Choi, K; Matsunuma, N; Sadato, D; Maemoto, Y; Ito, A; Yanagi, S; Starczynowski, DT; et al.
Cancer Discovery.
2022;
12:250-269.
IRAK1 and IRAK4 as emerging therapeutic targets in hematologic malignancies.
Bennett, J; Starczynowski, DT.
Current Opinion in Hematology.
2022;
29:8-19.
Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant AML.
Azhar, M; Kincaid, Z; Kesarwani, M; Wunderlich, M; Latif, T; Starczynowski, D; Azam, M.
Blood.
2021;
138:206-206.
Heterozygous Mutations in DDX41 Cause Erythroid Progenitor Cell Defects.
Chlon, TM; Stepanchick, E; Sulentic, A; Hueneman, K; Starczynowski, D.
Blood.
2021;
138:148-148.
Germline DDX41 mutations cause ineffective hematopoiesis and myelodysplasia.
Chlon, TM; Stepanchick, E; Hershberger, CE; Daniels, NJ; Hueneman, KM; Kuenzi Davis, A; Choi, K; Zheng, Y; Gurnari, C; Haferlach, T; et al.
Cell Stem Cell.
2021;
28:1966-1981.e6.